Compare · AYLA vs HWKN
AYLA vs HWKN
Side-by-side comparison of Ayala Pharmaceuticals Inc. (AYLA) and Hawkins Inc. (HWKN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AYLA and HWKN operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- HWKN carries a market cap of $3.14B.
- HWKN has hit the wire 6 times in the past 4 weeks while AYLA has been quiet.
- HWKN has more recent analyst coverage (7 ratings vs 5 for AYLA).
- Company
- Ayala Pharmaceuticals Inc.
- Hawkins Inc.
- Price
- -
- -
- Market cap
- -
- $3.14B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 6
- Recent ratings
- 5
- 7
Ayala Pharmaceuticals Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Hawkins Inc.
Hawkins, Inc. blends, manufactures, and distributes chemicals and other specialty ingredients in the United States and internationally. It operates through three segments: Industrial, Water Treatment, and Health and Nutrition. The Industrial segment offers industrial chemicals, products, and services to agriculture, chemical processing, electronics, energy, food, pharmaceutical, and plating industries. This segment primarily provides acids, alkalis, and industrial and food-grade salts. It also receives, stores, and distributes various chemicals, such as liquid caustic soda, sulfuric acid, hydrochloric acid, urea, phosphoric acid, aqua ammonia, and potassium hydroxide. In addition, this segment manufactures sodium hypochlorite and agricultural products, as well as various food-grade products that include liquid phosphates, lactates, and other blended products; repackages water treatment chemicals and bulk industrial chemicals; and performs custom blending of chemicals, and contract and private label bleach packaging. The Water Treatment segment offers chemicals, equipment, and solutions for potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool and agriculture water. The Health and Nutrition segment offers ingredient distribution, processing, and formulation solutions to manufacturers of nutraceutical, functional food and beverage, personal care, dietary supplement and other nutritional food, and health and wellness products. Its products portfolio includes minerals, botanicals and herbs, vitamins and amino acids, excipients, joint products, sweeteners, and enzymes. The company was founded in 1938 and is headquartered in Roseville, Minnesota.
Latest AYLA
- SEC Form 3 filed by new insider Martell Bridget A
- SEC Form 3 filed by new insider Orbach Pini
- SEC Form 3 filed by new insider Golan Roy
- SEC Form 10-K filed by Ayala Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13G filed by Ayala Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)
- SEC Form 15-12G filed by Ayala Pharmaceuticals Inc.
- Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets
- SEC Form 4: Amoon Growth Fund Limited Partnership returned 2,991,473 shares to the company
Latest HWKN
- Hawkins, Inc. to Participate in Sidoti & Company’s Year-End Virtual Investor Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Hawkins Inc.
- SEC Form 10-Q filed by Hawkins Inc.
- SEC Form 8-K filed by Hawkins Inc.
- Hawkins, Inc. Reports Second Quarter Fiscal 2027 Results
- Hawkins, Inc. Declares Quarterly Cash Dividend of $0.20 Per Share
- Hawkins, Inc. to Release Second Quarter Fiscal 2027 Financial Results on October 26, 2026
- Hawkins, Inc. Expands into Texas’ Dallas–Fort Worth Region with Acquisition of Eagle Labs, Inc.
- Hawkins, Inc. Expands in Florida with Acquisition of Dave Symonds & Associates, Inc.
- EXECUTIVE VP AND CFO Oldenkamp Jeffrey P. bought $153,510 worth of shares (1,290 units at $119.00), increasing direct ownership by 1% to 104,223 units (SEC Form 4)